Skip to main content Accessibility help
×
Home

Neuroleptic malignant syndrome or haloperidol toxicity: a case report and differential diagnosis

  • Ljiljana J Verner (a1), Claudia L Kollmar (a2) and Detlef E Dietrich (a2)

Abstract

Neuroleptic malignant syndrome (NMS) is a severe and potentially lethal complication of antipsychotic medication. Differential diagnosis is extremely important because severe catatonia, which has some similarities to NMS, may also be lethal but requires antipsychotic treatment. We present a case report of a 62-year-old woman who was admitted to hospital for differential diagnosis of NMS and suffered from severe haloperidol intoxication, which complicated the diagnostic evaluation. Further differential diagnostic aspects are summarised and their therapeutic implications are outlined.

Copyright

Corresponding author

Correspondence to: Prof. Dr. med. D. Dietrich, Department of Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany. Tel: +49 511 532 6571; E-mail: Dietrich.Detlef@mh-hannover.de

References

Hide All
Bottlender, R., Jager, M., Hofschuster, E., Dobmeier, P. and Moller, H.J. (2002) Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry. 35(3): 119121.
Caroff, S.N. and Mann, S.C. (1993) Neuroleptic malignant syndrome. The Medical Clinics of North America. 77(1): 185202.
Delay, J. and Pichot, P. (1960) Un neuroleptique majeur nonphenothiazine et non-reserpin, L'haloperidol, dans le traitement des psychoses. Annales Médico-Psychologiques. 118: 145152.
Gupta, S. and Nihalani, N.D. (2004) Neuroleptic malignant syndrome: a primary care perspective. Primary Care Companion to the Journal of Clinical Psychiatry. 6(5): 191194.
Hesse, L.M., Venkatakrishnan, K., van Moltke, L.L., Shader, R.I. and Greenblatt, D.J. (2001) CYP3A4 is the mayor CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metabolism and Disposition. 29(2): 133140.
Kalgutkar, A.S., Taylor, T.J., Venkatakrishnan, K. and Isin, E.M. (2003) Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metabolism and Disposition. 32(3): 243249.
Kish, S.J., Kleinert, M. and Minauf, M. (1990) Brain Neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. American Journal of Psychiatry. 147: 13581362.
Kudo, S. and Ishizaki, T. (1999) Pharmacokinetics of haloperidol: an update. Clinical Pharmacokinetics. 37(6): 435456.
Najara, J. and Enikeev, I. (1995) Risperidone and neuroleptic malignant syndrome: a case report. Journal of Clinical Psychiatry. 56: 534535.
Ram, A., Cao, Q., Keck, P.E. Jr., Pope, H.G. Jr., Otani, K., Addonizio, G., McElroy, S.L., Kaneko, S., Redlichova, M., Gershon, E.S., et al. (1995) Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. American Journal of Medical Genetics. 60(3): 228230.
Reichmann, I., Frilling, A., Hörmann, R. , Krause, U. and Broelsch, C.E. (2001) Frühoperationen als Behandlungsmaßnahme der thyreotoxischen Krise. Der Chirurg. 72(4): 402407.
Sager, S.M. (1991) Neuroleptic malignant syndrome: a diagnostic dilemma. Journal of the Royal Society of Medicine. 84: 500501.
Schulz, M. and Schmoldt, A. (1994) Zusammenstellung therapeutischer und toxischer Plasmakonzentrationsbereiche von Arzneistoffen. Anaesthetist. 43: 835844.
Viejo, L.F., Morales, V., Punal, P., Pererz, J.L. and Sancho, R.A. (2003) Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatrica Scandinavica. 107: 4549.
Zolezzi, M.S. and Al-Hathloul, A.M. (2002) Difficulties in diagnosing neuroleptic malignant syndrome. Saudi Medical Journal. 23(2): 234236.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed